Study Establishes Safety and Clinical Benefit of SIR-SpheresR microspheres in Treating Metastatic Liver Tumors in Patients who Failed Systemic Chemotherapy March 27, 2012, 12:05 p.m. EDT SAN FRANCISCO, Mar 27, 2012 (BUSINESS WIRE) -- SIR-SpheresR microspheres are safe and provide clinical benefit for patients with colon cancer liver metastases who have previously received liver-directed and systemic chemotherapy, according to the results of a prospective clinical study announced today at the Society of Interventional Radiology's 37th Annual Scientific Meeting. The data were presented by the interventional investigator Constantinos T. Sofocleous, M.D., in collaboration with Nancy Kemeny, M.D., GI Medical Oncologist from Memorial Sloan-Kettering Cancer Center in New York. SIR-Spheres microspheres are manufactured by Sirtex, a leading developer of targeted, innovative liver cancer therapies. The prospective single-center study assessed the safety, dose-limiting toxicities and the maximum tolerated dose of SIR-Spheres microspheres in a population whose cancer had progressed despite hepatic arterial and systemic chemotherapy treatments. Over the two year period, from September 2009-2011, 19 patients received SIR-Spheres microspheres in three escalating dose levels. The first group received 70%, the second group received 85%, and the third group received 100% of their specific calculated dose. Common side effects from the SIR-Spheres microspheres were mild-to-moderate (grade 1 or 2) fatigue and mild (grade 1) fever, which were self-limiting and transient. One patient experienced grade 3 nausea and pain, and two patients had elevated bilirubin levels attributed to progressive disease. Evaluations 4-8 weeks post-treatment showed 12 patients (65%) with stable disease, while five (29.4%) saw disease progression. Median progression-free and overall survival were 6 (95% ci:3.2-9.7) and 16 (95% ci:5.8-17.6) months, respectively. All patients received further chemotherapy, 9 further HAI therapy, with 4 having a decrease in CEA. Based on these findings, researchers concluded it is safe to administer the entire dose of SIR-Spheres microspheres in patients with colon cancer metastases who progressed despite prior pump and systemic chemotherapy. "This study helps to confirm that we need to identify more effective treatment options for patients with colorectal liver metastases," said Dr. Sofocleous. "These results have met our expectations regarding safety of SIRT in heavily pre-treated patients with good liver functions." For more information, visit www.Sirtex.com or find the latest updates on the SIR-Spheres microspheres Facebook page ( www.Facebook.com/SIRSpheresmicrospheres ).
About Selective Internal Radiation Therapy (SIRT) using SIR-Spheres microspheres Selective Internal Radiation Therapy (SIRT), also known as radioembolization, is a novel technology for inoperable liver cancer that delivers doses of radiation directly to the site of tumors. In a minimally invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue. Clinical trials have confirmed that patients with metastatic colorectal cancer treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone. SIR-Spheres microspheres are approved for use in Australia, the United States of America (FDA approval), and the European Union (CE Mark) and additionally supplied in countries such as Hong Kong, Malaysia, Singapore, Thailand, Taiwan, India, Israel and Turkey. Available at more than 400 treatment centers, over 20,000 doses of SIR-Spheres microspheres have been administered worldwide.Tuesday, March 27, 2012
多醣(Ambrotose(R)) 補腦!!
Review of the Effects of Polysaccharides on Brain Function is Published Mechanisms that might explain the cognitive benefits of Mannatech's glyconutrients and other polysaccharides are explored COPPELL, Texas, Mar 27, 2012 (BUSINESS WIRE) -- Mannatech, the leading innovator and provider of nutritional supplements based on Real Food Technology® solutions, recently announced the publication of a comprehensive literature review reporting the effects of polysaccharides on brain function. Dr. Erika Nelson, a neuroscientist, and her colleagues reviewed controlled studies assessing various roles of exogenous saccharide compounds and polysaccharide-rich extracts on brain function, with a significant focus on benefits derived from oral intake. Her review includes a discussion of five randomized, double-blind, placebo-controlled clinical trials that indicate that Ambrotose® complex, a Mannatech product, positively impacts well-being, memory, cognitive function and mood in healthy adults.* Numerous preclinical studies were also identified that indicate various polysaccharides can modify behavior, enhance synaptic plasticity and provide neuroprotective effects. "Mannatech has consistently demonstrated a strong commitment to evaluating the impact of oral polysaccharide compounds on human health," said Dr. Robert Sinnott, CEO and Chief Science Officer at Mannatech. "In 2010, we published a review--which has been of great interest to the scientific community--which consolidated the extant literature reporting significant impacts of oral polysaccharides on immune function. Today, we are once again pleased to offer an important consolidation of the literature investigating the impact of oral polysaccharides on brain health and function. This literature review both clarifies the current state of the science in this area and suggests appropriate avenues for future research that will help us better understand the benefits of these important compounds." Dr. Nelson earned her BS in Genetics from the University of Kansas in Lawrence and went on to obtain her PhD in Neuroscience at the University of Texas Southwestern Medical Center in Dallas. She has published a number of papers on neurodevelopmental disorders and brain epigenetics. A candidate for a Masters of Business Administration at the University of Texas at Dallas, Dr. Nelson is also a consultant for Mannatech. Co-authors of the review include Dr. Robert Sinnott; Dr. Talitha Best, a scientist with dual appointments at the University of South Australia, Adelaide, and Swinburne University of Technology, Victoria, Australia; and Jane Ramberg, Director of Product Substantiation at Mannatech. Individuals interested in Mannatech's products or exploring its business opportunity are encouraged to learn more at Mannatech.com.
About Mannatech Mannatech, Incorporated, develops high-quality health, weight and fitness, and skin care products that are based on the solid foundation of nutritional science and development standards. Mannatech is dedicated to its platform of Social Entrepreneurship based on the foundation of promoting, aiding and optimizing nutrition where it is needed most around the world. Mannatech's proprietary products are available through independent sales Associates around the globe including the United States, Canada, South Africa, Australia, New Zealand, Austria, Denmark, Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan, Taiwan, Singapore, Estonia, Finland, the Republic of Ireland, Czech Republic, the Republic of Korea, Mexico and Namibia. For more information, visit Mannatech.com.長效抗體藥物(AMG 145, anti- PCSK9) 降膽固醇 每月一次!!
TMF若難產 國發基金不排除直接投資生技標的!!
林桓；TMF募資，沒那麼悲觀2012-03-2708:17時報資訊【時報-各報要聞】國發基金執秘林桓昨（26）日表示，過去這一年景氣不好確實讓台灣生技創投基金（TMF）募資不甚順利，但距離募資期限6月16日還有兩個多月，隨著景氣好轉，募資情況未必如外界想像的這麼悲觀。 林桓表示，TMF的規模是50億元，他們必須在所承諾的期限6月16日之前找到投資人，募集40億元，國發基金才會投入10億元。過去這一年全球景氣低迷，在資本市募資確實不易，但這並不代表最後一定募不到，因為近來景氣已有好轉的現象。 林桓表示，TMF在募資過程中，感興趣的投資人很多，只是要簽署承諾投資協議時就轉趨慎重，在景氣不好時，投資人這種觀望的態度是很合理的，他認為隨著景氣復甦，投資人觀望的情況也許會有所改變，到6月16日還有兩個多月，募資情況沒有那麼悲觀。 對於外界認為宇昌案影響了TMF的募資並讓生技專家們感到灰心，林桓表示，宇昌案是過去行政院專案核定程序所引發的爭議，是程序上的問題，而TMF的程序沒有問題，外界實在無需做過度的聯想。 林桓表示，現在說TMF募不到資金，言之過早，但屆時如果真的無法順利募得資金，國發基金將會在方向上及策略上做一些調整，生技起飛鑽石行動方案仍將繼續推動。 林桓說，國發基金投資生技產業除了透過創投基金間接投資生技產業，如果有好的標的，也可以直接投資，目前國發基金所投資的生技創投有有11家，絕不會讓好的標的卻沒有投資的情況出現，國發基金投資生技產業的方向並沒有改變。(新聞來源：工商時報─記者于國欽／台北報導)
.jpg)
Posts
